TriviumVet represented at the VMX Conference presented by North American Veterinary Community
It was great to have TriviumVet represented by our CEO Louise Grubb and CTO Stuart Fitzgerald at a very informative VMX conference
Recent visit with our Researchers at North Carolina State University College of Veterinary Medicine.
Our CTO Stuart Fitzgerald and Regulatory Affairs Manager Susan Kennedy had a successful trip to the US
TriviumVet represented by Susan Kennedy at the information day for SMEs in the veterinary medicines sector organised by European Medicines Agency.
Susan presented TriviumVet’s experience of receiving scientific advice from the EMA.
TriviumVet work with Texas A&M University on a clinical trial evaluating a new drug – RapaVet® – to treat dilated cardiomyopathy in dogs.
TriviumVet are delighted to be working with Texas A&M University on this exciting clinical trial.
IHS Markit Article – TriviumVet gearing up for pet pipeline launches to bridge therapeutic gaps
Ireland’s TriviumVet is a therapeutics and diagnostics start-up targeting a range of unmet needs in companion animal health.
FDA’s Center for Veterinary Medicine deems TriviumVet’s feline HCM program eligible for expanded conditional approval pathway
TriviumVet™ are delighted to announce that the Food and Drug Administration’s Center for Veterinary Medicine has determined that our feline hypertrophic cardiomyopathy (HCM) therapeutic candidate, Felycin™ can pursue the expanded conditional approval pathway.
TriviumVet announce collaboration with the Dog Aging Project
TriviumVet, today announced an exciting research collaboration with the Dog Aging Project, TRIAD Trial.
TriviumVet announce publication of recent research into gastric acid suppression in dogs
TriviumVet are delighted to announce the publication of a clinical study assessing our first product in development, a gastric acid suppressant to treat gastric ulceration in dogs.
TriviumVet advance their first feline product, a potential treatment for HCM in cats
TriviumVet commence clinical study of first-in-disease treatment for HCM in cats